Publications

Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized …

MHG Katz, Q Shi, J Meyers, JM Herman, M Chuong, BM Wolpin, S Ahmad, ...

Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study

Hilmi M, Naoun N, Boilève A, Géraud A, Bayle A, Pagès A, Aupomerol M, Rouanne M, et al.

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)

MH Kulke, FS Ou, D Niedzwiecki, L Huebner, P Kunz, HF Kennecke, ...

Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation

D Arnold, P Hammel, T Golan, M Reni, E Van Cutsem, T Macarulla, ...

Extended Overall Survival Results from the POLO Study of active Maintenance Therapy with Olaparib in Patients with metastatic Pancreatic Cancer and a Germline BRCA Mutation

D Arnold, T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.

JP Lyman, A Doucette, B Zheng-Lin, CR Cabanski, MA Maloy, NL Bayless, ...

First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.

S Pant, M Furqan, RM Abdul-Karim, V Chung, CE Devoe, ML Johnson, ...

FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium

QP Janssen, JL Van Dam, D Doppenberg, LR Prakash, CHJ Van Eijck, ...

Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).

CG Kohn, FS Ou, C Ma, NB Larson, TJ Zemla, C Yuan, D Niedzwiecki, ...

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...

Helping patients understand Pancreatic Cancer using animated pancreas patient Education with Visual formats of Learning

S Munigala, TB Gardner, EM O'Reilly, C Fernández-del Castillo, AH Ko, ...

Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?

Keane F, Park W, O'Reilly EM

Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.

W Park, F Keane, C Bandlamudi, M Donoghue, P Tallón de Lara, ...

Improving understanding of pancreatic cancer among patients using an animated patient’s guide to benefit informed decisions and health outcomes.

S Munigala, EM O'Reilly, DE Bakelman, J Holt, AH Ko, N Searle, A Gelrud

Incidence of Pancreatic Cancer by Age and Sex in the US From 2000 to 2018

F Keane, M Du, EM O’Reilly

Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma

McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, et al.

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, et al.

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma: B …

B Zheng-Lin, M Rainone, AM Varghese, KH Yu, W Park, M Berger, ...

MITI minimum information guidelines for highly multiplexed tissue images

Schapiro D, Yapp C, Sokolov A, Reynolds SM, Chen YA, Sudar D, Xie Y, …

Mo1225: ACUTE PANCREATITIS CAN UNMASK UNDERLYING PANCREATIC ADENOCARCINOMA IN PATIENTS WITH UNCLEAR ETIOLOGY OF PANCREATITIS: A MULTICENTER ELECTRONIC HEALTH RESEARCH NETWORK …

RR Singh, A Klein, EM O'Reilly

Molecular characterization of gallbladder cancer

NA Giraldo, A Mohanty, C Vanderbilt, R Brannon, R Benayed, E Vakiani, ...

Multi-institutional comparison of ablative radiation therapy in 5 versus 15-25 fractions for locally advanced pancreatic cancer

M Reyngold, E O'Reilly, R Herrera, A Kaiser, M Zinovoy, PB Romesser, ...

Neo‐adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma

S Temraz, F Nassar, MS Hammoud, D Mukherji, EM O'Reilly, H Dbouk, ...

Neoadjuvant radiotherapy after (m) FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS consortium study

QP Janssen, JL van Dam, LR Prakash, D Doppenberg, CH Crane, ...

Optimal tumor metastatic gene programs in pancreatic cancer

A Jimenez-Sanchez, Y Xie, R Sharma, TY Chu, V Liu, W Park, A Hayashi, ...

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, et al.

P-22 phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line …

E O'Reilly, T Golan, M Ikeda, M Milella, J Taieb, Z Wainberg, L Wang, ...

Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes.

EM O'Reilly

Persistent Disparities in Treatment and Survival for Patients with Pancreatic Cancer Despite Insurance Expansion Policies

L Saadat, J Chou, M Gonen, K Soares, V Balachandran, TP Kingham, ...

Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.

RK Kelley, E Van Cutsem, MS Lee, I Wolf, M Fakih, J de Vos-Geelen, ...

Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.

VP Balachandran, LA Rojas, Z Sethna, K Soares, E Derhovanessian, ...

Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic …

EM O'Reilly, T Golan, M Ikeda, M Milella, J Taieb, ZA Wainberg, LW Wang, ...

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)

Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, et al.

Precision approaches to pancreatic cancer therapy: what now and what next?

F Keane, W Park, EM O’Reilly

Precision Medicine and Immunotherapy in GI Cancers

O'Reilly EM, Ko AH

Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma

Hilmi M, Neuzillet C, Lefèvre JH, Svrcek M, Vacher S, Benhaim L, Dartigues P, Samalin E, et al.

Radiation Therapy (RT) Quality Assurance (QA) Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus Hypofractionated Radiation Therapy for Borderline …

L Tchelebi, KS Smith, Q Shi, T Fitzgerald, MD Chuong, T Zemla, E O'Reilly, ...

Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan …

KH Yu, P Cockrum, A Surinach, N Lamarre, S Wang, EM O'Reilly

Salvage ablative radiation therapy for loco-regionally recurrent pancreatic ductal adenocarcinoma following surgical resection.

V Ng, M Zinovoy, C Hajj, PB Romesser, AJC Wu, JJ Cuaron, WR Jarnagin, ...

Sorafenib in Dupuytren and Ledderhose Disease

Schoenfeld JD, Agaram NP, Lefkowitz RA, Kelly CM, Healey JH, Gounder MM

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, et al.

Stereotactic ablative radiation for pancreatic cancer on a 1.5 áTelsa magnetic resonance-linac system

KR Tringale, N Tyagi, PB Romesser, A Wu, EM O'Reilly, AM Varghese, ...

Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system

Tringale KR, Tyagi N, Marsha Reyngold, Romesser PB, Wu A, O'Reilly EM, Varghese AM, Godoy Scripes P, et al.

Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization

AG Shuman, MS Aapro, B Anderson, K Arbour, PC Barata, A Bardia, ...

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, et al.

The frequency of second primary malignancies and colonic polyps in Lynch syndrome with MSI tumors following immune checkpoint blockade.

E Harrold, Z Patel, A Maio, A Cercek, R Yaeger, NH Segal, DL Reidy, ...

The lung pro-thrombotic niche drives cancer-associated thromboembolism and metastasis via extracellular vesicle ITGB2.

S Lucotti, Y Ogitani, CM Kenific, L Bojmar, M Cioffi, P Lauritzen, H Molina, ...

The lung pro-thrombotic niche drives cancer-associated thromboembolism via exosomal ITGB2

S Lucotti, Y Ogitani, CM Kenific, L Bojmar, M Cioffi, P Lauritzen, H Molina, ...

Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study.

S Augustinus, HWM Van Laarhoven, GA Cirkel, JW de Groot, ...

Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma

TB de Castria, DN Khalil, JJ Harding, EM O’Reilly, GK Abou-Alfa